SAN DIEGO, May 12, 2011 /PRNewswire/ — Naviscan, Inc.,
the leader in 3D Molecular Breast Imaging (MBI), has entered into a
distribution agreement with Chindex Medical Limited to market and
service Naviscan’s high-resolution organ-specific PET scanner in
the People’s Republic of China, including Hong Kong and Macau.
The agreement represents the introduction of PEM (Positron
Emission Mammography), the scanner’s breast application, as a new
tool available to Chinese women in their fight against breast
cancer.
Naviscan manufactures the only commercially-available PEM
scanner and PEM-guided biopsy system. The scanner uses PET
technology to produce tomographic images that allow physicians to
visualize and biopsy breast tumors as small as 1.3 mm, the width of
a grain of rice. In recently published data, PEM has been
found to be significantly more precise at identifying benign and
cancerous lesions, in what scientists call “specificity”, therefore
reducing the number of unnecessary biopsies. This finding is
a welcomed outcome for women and physicians looking for ways to
reduce the patient trauma and cost associated with unnecessary
procedures.
Chindex Medical Limited is a specialized full-service
distributor of high tech medical equipment in Greater China,
including a strong presence in the minimally-invasive surgical and
imaging sectors as the exclusive distributor for the Intuitive
Surgical daVinci® Surgical Systems, and Siemens high-end
ultrasound and Hologic mammography products. The Naviscan PET
scanner is an ideal complement to Chindex Medical Limited’s breast
and surgery expertise and an ideal partner to continue its
expansion in Asia.
About Naviscan, Inc.
Naviscan, founded in 1995, develops and markets compact,
high-resolution PET scanners intended to provide organ-specific
molecular imaging and guide radiological and surgical procedures.
The Naviscan PET scanne
‘/>”/>
